AOR.L Regulatory News (AOR)

7 Aug 2006 07:02

Aortech International PLC07 August 2006 7 August 2006 AorTech International plc ("AorTech" or "the Company") First Human Use of Elast-Eon(TM) Polymer London - AorTech International plc (AIM: AOR), the medical device developmentand biomaterials intellectual property and licensing company, announces thefirst FDA approved human use of its polymer technology Elast-Eon pursuant toits exclusive license agreement with St. Jude Medical (STJ: NYSE) which wasannounced on March 20 2006. Frank Maguire, AorTech CEO said: "This event represents another significant step forward in the development ofthe company and the validation of the Elast-Eon technology. In addition to thedirect benefit of revenues from Elast-Eon sales, the commencement of the humanuse phase will provide valuable credibility for Elast-Eon as we expand its useinto other medical markets". The global market for cardiac pacing and ICD products is in excess of £5.5billion and grew approximately 8% in 2005. In addition, the company expects clinical use of its Elast-Eon material tooccur in orthopaedic and urology markets under separate licenses over the nextyear. -Ends- Enquiries: AorTech International plc Tel: 801 581 0854Frank Maguire, Chief Executive Officer Hogarth PR Tel: 020 7357 9477Melanie Toyne-Sewell / Andrew Jaques/Sarah Richardson This information is provided by RNS The company news service from the London Stock Exchange